Emmessar Biotech

Which are the latest news on Emmessar Biotech?

Why is Emmessar Biotech & Nutrition Ltd falling/rising?

As of 05-Sep, Emmessar Biotech & Nutrition Ltd's stock price is at 23.77, reflecting a 2.18% decline and significant underperformance against the Sensex, with a year-to-date drop of 19.01%. The stock shows a negative trend over longer periods, including a 10.84% decline over the past year, while trading activity indicates reduced investor participation.

As of 05-Sep, Emmessar Biotech & Nutrition Ltd's stock price is falling, currently at 23.77, which reflects a decrease of 0.53 or 2.18%. The stock has underperformed against the benchmark Sensex, with a one-week decline of 4.88% compared to the Sensex's 0.97% drop. Over the past month, the stock has decreased by 3.84%, while the Sensex fell by 2.44%. Year-to-date, the stock has seen a significant decline of 19.01%, in contrast to the Sensex's 10.21% decline. <BR><BR>Additionally, the stock's performance over longer periods shows a negative trend, with a 10.84% drop over the past year and a 30.80% decline over the last five years, while the Sensex has gained 31.63% in the same timeframe. <BR><BR>Today's trading activity indicates a concerning trend in investor participation, with a delivery volume of 606 on September 3, which is down by 64.51% compared to the five-day average. Although the stock outperformed its sector by 1.46% today, it remains below the 100-day and 200-day moving averages, suggesting a lack of strong upward momentum. Overall, these factors contribute to the stock's current downward trajectory.

Who are in the management team of Emmessar Biotech?

The management team of Emmessar Biotech includes MSR Ayyangar (Chairman & Managing Director), Anuradha Raghavan, Sarada Raghavan, Rajalakshmi Srinivasa Raghavan (all Non Executive Directors), Anantharama Sethmani Subramanian, Milind S Desai (Independent Directors), Jayavel Balaiah Nadar (Executive Director & CFO), and Priyanka Omprakash Sharma (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of Emmessar Biotech includes the following individuals:<BR><BR>1. **MSR Ayyangar** - Chairman & Managing Director<BR>2. **Anuradha Raghavan** - Non Executive Director<BR>3. **Sarada Raghavan** - Non Executive Director<BR>4. **Anantharama Sethmani Subramanian** - Independent Director<BR>5. **Jayavel Balaiah Nadar** - Executive Director & CFO<BR>6. **Rajalakshmi Srinivasa Raghavan** - Non Executive Director<BR>7. **Priyanka Omprakash Sharma** - Company Secretary & Compliance Officer<BR>8. **Milind S Desai** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Emmessar Biotech do?

Emmessar Biotech & Nutrition Ltd manufactures Super Specialty Fine Chemicals and operates in the Commodity Chemicals industry. As of June 2026, it reported net sales and profit of 0 Cr, with a market cap of INR 13 Cr.

Overview: <BR>Emmessar Biotech & Nutrition Ltd is engaged in the manufacturing of Super Specialty Fine Chemicals and operates within the Commodity Chemicals industry, classified as a Micro Cap company.<BR><BR>History: <BR>The company was originally established on 17th March 1992 as Emmessar Chemical Industries Ltd (ECIL). It has developed numerous Specialty Fine Chemicals and received official recognition for its R&D from the DSIR, Ministry of Science & Technology, Government of India, in early 1996. The latest quarterly results reported net sales and net profit of 0 Cr for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 13 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 30.00 <BR>Industry P/E: 43 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.90 <BR>Return on Equity: 4.80% <BR>Price-to-Book: 1.53 <BR><BR>Contact Details: <BR>Address: Plot No T-3/2 MIDC Area, P O Box No 39 Taloja Raigad Maharashtra : 410208 <BR>Tel: 91-022-20870587 <BR>Email: investors@ebnl.co.in/emmessar@vsnl. <BR>Website: http://www.ebnl.co.in

Who are the peers of the Emmessar Biotech?

Emmessar Biotech's peers include Jayshree Chem., Square Four Pro., Tulasee Bio-Eth., Kobo Biotech, Link Pharma Chem, Omkar Pharmachem, Sreechem Resins, Kuwer Industries, and Lime Chemicals. Emmessar has average management risk and growth, with a 1-year return of -11.14%, while Kobo Biotech leads with a 1-year return of 134.04%.

Peers: The peers of Emmessar Biotech are Jayshree Chem., Square Four Pro., Tulasee Bio-Eth., Kobo Biotech, Link Pharma Chem, Omkar Pharmachem, Sreechem Resins, Kuwer Industries, and Lime Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sreechem Resins, while Average management risk is found at Emmessar Biotech, Jayshree Chem., and Link Pharma Chem. Below Average management risk is noted at Kuwer Industries and Lime Chemicals, and the rest have management risks that do not qualify. Growth is Average at Emmessar Biotech, while Below Average growth is seen at Jayshree Chem., Link Pharma Chem., and the rest. Capital Structure ratings are Below Average for Emmessar Biotech, Jayshree Chem., Link Pharma Chem., Kuwer Industries, and Lime Chemicals, while Sreechem Resins has a Good rating, and the rest do not qualify.<BR><BR>Return Snapshot: Kobo Biotech has the highest 1-year return at 134.04%, while Tulasee Bio-Eth. has the lowest at 44.69%. Emmessar Biotech's 1-year return is -11.14%, which is lower than both of these peers. Additionally, Omkar Pharmachem and Sreechem Resins have negative six-month returns.

How big is Emmessar Biotech?

As of 31st August, Emmessar Biotech & Nutrition Ltd has a market capitalization of 13.00 Cr, with recent Net Sales of 0.33 Cr and a Net Profit of 0.39 Cr. Shareholder's Funds are 7.71 Cr and Total Assets amount to 9.22 Cr as of March 2025.

As of 31st August, Emmessar Biotech & Nutrition Ltd has a market capitalization of 13.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.33 Cr and a Net Profit of 0.39 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 7.71 Cr and Total Assets of 9.22 Cr.

When is the next results date for Emmessar Biotech & Nutrition Ltd?

The next results date for Emmessar Biotech & Nutrition Ltd is August 7, 2026.

The next results date for Emmessar Biotech & Nutrition Ltd is scheduled for August 7, 2026.

How has been the historical performance of Emmessar Biotech?

Emmessar Biotech has experienced significant fluctuations in financial performance, with net sales and operating income peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25, while operating profit turned negative and total assets and liabilities increased. The company has shown a consistent zero balance in cash and cash equivalents, indicating poor cash flow.

Answer:<BR>The historical performance of Emmessar Biotech shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Emmessar Biotech's net sales have varied considerably, peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25. The total operating income followed a similar trend, with a high of 6.99 Cr in Mar'21 and a drop to 0.61 Cr in Mar'25. The company's total expenditure, excluding depreciation, has also seen fluctuations, reaching a high of 6.14 Cr in Mar'21 and decreasing to 1.56 Cr in Mar'25. Operating profit (PBDIT) has been negative in recent years, with a loss of 0.95 Cr in Mar'25, contrasting with a profit of 0.85 Cr in Mar'21. Profit after tax has decreased from 1.45 Cr in Mar'21 to 0.32 Cr in Mar'25. The company's total assets have increased from 5.19 Cr in Mar'20 to 9.22 Cr in Mar'25, while total liabilities have also risen from 5.19 Cr to 9.22 Cr in the same period. Cash and cash equivalents have shown a consistent zero balance from Mar'20 to Mar'25, indicating a lack of cash flow from operations. Overall, Emmessar Biotech has experienced a decline in sales and profitability, alongside an increase in total assets and liabilities.

Who are the top shareholders of the Emmessar Biotech?

The top shareholders of Emmessar Biotech include Emmessar Technologies Limited with 21.79%, individual investors with 37.15%, and Sandeep Rao as the highest public shareholder at 2.04%. There are no foreign institutional investors, and no promoter holdings are pledged.

The top shareholders of Emmessar Biotech include the promoters, with Emmessar Technologies Limited holding the largest stake at 21.79%. Additionally, individual investors collectively own 37.15% of the company. The highest public shareholder is Sandeep Rao, who holds 2.04%. There are also two mutual fund schemes that hold a very small percentage of shares (0.05%), and currently, there are no foreign institutional investors (FIIs) involved. Notably, there are no pledged promoter holdings.

Is Emmessar Biotech overvalued or undervalued?

As of April 25, 2023, Emmessar Biotech is rated as risky and overvalued, with a PE ratio of 16.32, a Price to Book Value of 2.12, a troubling ROCE of -104%, and has underperformed the Sensex by declining 26.44% year-to-date.

As of 25 April 2023, the valuation grade for Emmessar Biotech has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial stability. The company is currently assessed as overvalued. Key ratios include a PE ratio of 16.32, a Price to Book Value of 2.12, and a troubling ROCE of -104.00%. <BR><BR>In comparison to its peers, Emmessar Biotech's PE ratio is significantly lower than that of Solar Industries, which stands at 123.77, and Godrej Industries at 46.63, both of which are considered very expensive. The negative EV to EBIT and EV to EBITDA ratios of -9.07 and -9.44, respectively, further highlight the company's financial challenges. Notably, Emmessar's stock has underperformed relative to the Sensex, particularly year-to-date, where it has declined by 26.44% compared to the Sensex's gain of 5.61%.

What is the technical trend for Emmessar Biotech?

As of May 30, 2025, Emmessar Biotech's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.

As of 30 May 2025, the technical trend for Emmessar Biotech has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish. The Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST shows a mildly bullish signal weekly but mildly bearish monthly. Dow Theory reflects a mildly bearish trend weekly, contrasting with a mildly bullish stance monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish indicators on the weekly MACD and KST.

Has Emmessar Biotech declared dividend?

No Dividend History Available